The Center for Integrated Diagnostics (CID) is a molecular pathology clinical service laboratory offering specialized molecular DNA testing.

Microscope

Center for Integrated Diagnostics

The Center for Integrated Diagnostics' (CID) mission is to work across the Massachusetts General Hospital to foster development of clinical actionable diagnostics and accelerate the adoption of personalized medicine.  

The CID's focus is on tumor diagnostics that result in the use of targeted therapies. Together with the Translational Research Laboratory (TRL), a broad genotyping screen in tumors called SNaPshot was clinically launched in March of 2009. This screen has since been expanded several times to include more actionable loci.

The laboratory performs a number of assays focused on tumor diagnostics, including SNaPshot, MGMT and MLH1 promoter methylation, microsatellite instability, and a growing number of FISH screens, including ROS1 and ALK. In addition, the laboratory performs pre-transplant STR genotyping and post-transplant chimerism analysis. Array CGH and hemochromatosis testing are also available in our laboratory.

Molecular Testing Requisition Form

The laboratory also does reference testing. Providers outside of MGH who are interested in sending specimens will find information in the Supplement for requesting testing.

Referring health care providers can contact the laboratory by telephone. Detailed instructions for sample handling and delivery are on the Laboratory Handbook CID page.

For current pricing please call 617-643-2716.

Faculty

Robot

Location & Contact Information

Center for Integrated Diagnostics (CID), and
Translational Research Laboratory
Massachusetts General Hospital
Jackson Building, Floor 10
55 Fruit Street
Boston, MA 02114

Phone: 617-643-2716
Fax: 617-643-1623
Hours: Monday through Friday, 8:30 am to 5:00 pm

 

 

Publication References

  1. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-53, 2009
  2. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ: Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2:146-58, 2010
  3. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-703, 2010
  4. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ: Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping. Oncologist, 2011
  5. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ: MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib. J Clin Oncol, 2011
  6. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, Camidge DR, Solomon BJ, Maki RG, Bang YJ, Kim DW, Christensen J, Tan W, Wilner KD, Salgia R, Iafrate AJ: Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 6:942-6, 2011
  7. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, Aldape KD, Betensky RA, Louis DN, Iafrate AJ: Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20:810-7, 2011
  8. Bergethon K, Shaw AT, Ignatius Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ: ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers. J Clin Oncol, 2012
  9. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ: Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping. Oncologist 17:72-9, 2012
  10. Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL, Curry WT, Wen PY, Ligon KL, Ellisen L, Louis DN, Iafrate AJ: Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol, 2012
  11. Chi AS, Batchelor TT, Kwak EL, Clark JW, Wang DL, Wilner KD, Louis DN, Iafrate AJ: Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol 30:e30-3, 2012

Updated 6/25/2013